Article Text

Download PDFPDF
Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated intravascular coagulation
  1. Yalcin Solak1,
  2. Abduzhappar Gaipov1,
  3. Orhan Ozbek2,
  4. Mustafa Aziz Hassan3,
  5. Mehdi Yeksan1
  1. 1Division of Nephrology, Department of Internal Medicine, Selcuk University, Meram School of Medicine, Konya, Turkey
  2. 2Department of Radiology, Selcuk University, Meram School of Medicine, Konya, Turkey
  3. 3Department of Urology, Selcuk University, Meram School of Medicine, Konya, Turkey
  1. Correspondence to Dr Abduzhappar Gaipov, abduzhappar{at}


Massive haematuria is a life-threatening condition, demanding immediate management of bleeding. The mortality is very high in the case of delayed management of bleeding, especially in elderly patients with concomitant comorbidity. The treatment options of haematuria are wide, and depend on underlying conditions. However, therapeutic choices are limited in the presence of massive and intractable haematuria caused by disseminated intravascular coagulation (DIC). Ankaferd blood stopper (ABS) is a novel, commercially available, haemostatic agent, which has been approved by the Ministry of Health for local use in Turkey. Here, for the first time in the literature, we report a case of diffuse intravesical bleeding stopped by intravesical use of ABS in a 72-year-old man, haemodialysis patient complicated with sepsis and DIC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.